compounding semaglutide fda enforcement news today Important Update: Changes to Compounded Availability Troubling Findings in Study of

GLP-1 receptor agonists have been shown to provide superior glycemic control and weight loss relative to the DPP-4 inhibitors

At 8 mg doses, the range was 17-60% depending on the specific trial and titration speed

The pharmacy sourcing is named (Epiq Scripts, a state-licensed 503A compounder), one of the few programs that publicly cites its dispensing pharmacy by name rather than obscuring it behind a licensed partner network phrase

Transfus Med Rev 27(3):137145

Metabolic Changes: The metabolic benefits (e.g., improved insulin sensitivity) may diminish, potentially increasing the risk of weight-related health issues

Is nausea normal in the first weeks, and will it affect results